Document is current

Article History

Received: 26 May 2021

Revised: 19 August 2021

Accepted: 21 September 2021

First Online: 16 November 2021

Declarations

:

: The scientific guarantor of this publication is Lars Lönn.

: The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

: One of the authors has significant statistical expertise.No complex statistical methods were necessary for this paper.

: Institutional Review Board in each respective country granted approval for the collection of data related to PAE procedures in the specified timeframe for the purpose of analysis and publication. As the study was retrospective, it did not include any additional interaction with individual patients or include data from which individual patients could be identified in any way.

: Institutional Review Board approvals were obtained.

: Some study subjects or cohorts have been previously reported in:14 subjects in the Copenhagen cohort: Malling B, Røder MA, Lindh M, et al (2019) Palliative prostate artery embolization for prostate cancer: a case series. <i>Cardiovasc Intervent Radiol</i> 42:1405–1412.25 subjects in the Oslo cohort: Kløw NE, Grøtta OJ, Bay D, Sandbæk G, Bjerklund Johansen TE, Hagen T, Baco E. Outcome after prostatic artery embolization in patients with symptomatic benign prostatic hyperplasia. <i>Acta Radiol</i> 2019 Sep;60(9):1175–1180.37 subjects in the Helsingborg cohort: Hans Lindgren and Mats Bläckberg. Introduction of prostate artery embolization (PAE) in Sweden. Scand J Urol. 2019 Apr-Jun;53(2–3):151–155.All three studies are unrelated to the current investigation and concern clinical outcomes of PAE.

: • Retrospective• Observational• Multicenter study